A Phase 1 interventional study of KAE609 and Placebo in Malaria, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Malaria by Novartis — 3 open to participants now, 3 under way, none of them phase 3. Malaria · Novartis.
Among the 24 studies in Malaria by Novartis, this one is the 11th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2020, is one of 6 in phase 1, and was the 16th registered.
1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.
Browse Malaria studies →3 of the 24 studies in Malaria by Novartis are open now, in 6 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Burkina Faso, Côte D'Ivoire, Gabon and 3 more countries
Ages 2–100
Novartis Pharmaceuticals
Ages 0 days–12 mo
Novartis Pharmaceuticals
Ages 10–99 · Healthy volunteers
By country, each count listing its studies:
Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 5 · Phase 4 5
First in 2001; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is below the median of 252 across 938 interventional studies indexed under Malaria.
Median enrollment 57 across the 21 interventional studies, 254 across the 2 observational. Of the 21 that completed or were terminated, 10 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
1 of the studies in Malaria by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07896746Novartis PharmaceuticalsFactors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and Rwanda | 2027-01-30 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Malaria by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a randomized, subject and investigator-blinded, placebo-controlled, single and multiple ascending intravenous (iv) dose study in healthy subjects to assess the safety and tolerability of KAE609 given in the vein.
The study consisted of 2 parts: single-ascending dose (SAD) part and multiple ascending dose (MAD) part.
In Part A (Single-ascending dose (SAD) part), it was planned to recruit 6 active, 2 placebo subjects in each cohort:
In Part B (Multiple-ascending dose (MAD) part), Subjects were assigned to one of the following treatment arms in a ratio of 2:1 (6 active, 3 placebo):
Eligible subjects were randomized to receive a single or q24h x 5 doses of either KAE609 or placebo. Safety, tolerability and pharmacokinetics were assessed over the period of 8 days for single dose and 12 days for multiple dose up to end of study visit for each subject.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single iv bolus dose of KAE609 or placebo administered at the clinical site by the study personnel.
Drug: KAE609 · Drug: Placebo
Single iv bolus dose of KAE609 or placebo administered at the clinical site by the study personnel.
Drug: KAE609 · Drug: Placebo
Single iv infusion dose of KAE609 or placebo administered at the clinical site by the study personnel.
Drug: KAE609 · Drug: Placebo
Single iv infusion dose of KAE609 or placebo administered at the clinical site by the study personnel.
Drug: KAE609 · Drug: Placebo
Single iv infusion dose of KAE609 or placebo administered at the clinical site by the study personnel.
Drug: KAE609 · Drug: Placebo
Multiple iv bolus doses of KAE609 or placebo administered at the clinical site by the study personnel.
Drug: KAE609 · Drug: Placebo
Multiple iv infusion doses of KAE609 or placebo administered at the clinical site by the study personnel.
Drug: KAE609 · Drug: Placebo
* iv bolus administration over approximately 2 min for doses \< 75 mg (Cohorts A1, A2 and B1) * iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)
matching placeo for iv administration
Number of Participants With On-Treatments Adverse Events, Serious Adverse Events, and Deaths
The distribution of adverse events was done via the analysis of frequencies for Adverse Event (AEs), Serious Adverse Event (SAEs) and Deaths, through the monitoring of relevant clinical and laboratory safety parameters.
Time frame: From study treatment start date till 30 days safety follow-up, assessed for up to 4 months
Part A - Pharmacokinetic of KAE609: Maximum Observed Plasma Concentration (Cmax)
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Cmax was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Time frame: Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Part A - Pharmacokinetic of KAE609: Time to Reach the Maximum Concentration After Drug Administration (Tmax)
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Tmax was calculated from plasma concentration-time data using non-compartmental methods based on the actual time of sample collection and summarized using descriptive statistics.
Time frame: Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Part A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUClast was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Time frame: Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Part A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf)
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUCinf was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Time frame: Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Part A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC0-24hrs)
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUC0-24hrs was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Time frame: Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Part A - Pharmacokinetic of KAE609: Terminal Elimination Half-life (T1/2)
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. T1/2 was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Time frame: Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Part A - Pharmacokinetic of KAE609: Clearance From Plasma (CL) Following Drug Administration
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. CL was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Time frame: Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Part A - Pharmacokinetic of KAE609: Apparent Volume of Distribution During Terminal Phase (Vz)
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Vz was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Time frame: Day 1 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Part B - Pharmacokinetic of KAE609: Maximum Observed Plasma Concentration (Cmax)
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Cmax was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Time frame: Days 1 and 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Part B - Pharmacokinetic of KAE609: Time to Reach the Maximum Concentration After Drug Administration (Tmax)
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Tmax was calculated from plasma concentration-time data using non-compartmental methods based on the actual time of sample collection and summarized using descriptive statistics.
Time frame: Days 1 and 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Part B - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUClast was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Time frame: Day 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Part B - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC0-24hrs)
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUC0-24hrs was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Time frame: Days 1 and 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Part B - Pharmacokinetic of KAE609: Terminal Elimination Half-life (T1/2)
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. T1/2 was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Time frame: Days 1 and 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Part B - Pharmacokinetic of KAE609: Clearance From Plasma (CL) Following Drug Administration
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. CL was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Time frame: Day 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
Part B - Pharmacokinetic of KAE609: Apparent Volume of Distribution During Terminal Phase (Vz)
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Vz was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
Time frame: Day 5 (-1 hr, 2 min, 10 min, 30 min, 1 hr, 3 hr, 6 hr, 12 hr)
This study was conducted in one center in Belgium.
| Milestone | Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg) | Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg) | Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg) | Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg) | Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg) | Part A (Single-ascending Dose (SAD): Pooled Placebo | Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg) | Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg) | Part B (Multiple-ascending Dose (MAD): Pooled Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 9 | 6 | 6 | 6 |
| Pk analysis set | 6 | 6 | 6 | 6 | 6 | 0 | 6 | 6 | 0 |
| Completed | 6 | 6 | 6 | 6 | 6 | 8 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
The distribution of adverse events was done via the analysis of frequencies for Adverse Event (AEs), Serious Adverse Event (SAEs) and Deaths, through the monitoring of relevant clinical and laboratory safety parameters.
| Participants | Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg) | Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg) | Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg) | Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg) | Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg) | Part A (Single-ascending Dose (SAD): Pooled KAE609 | Part A (Single-ascending Dose (SAD): Pooled Placebo | Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg) | Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg) | Part B (Multiple-ascending Dose (MAD): Pooled KAE609 | Part B (Multiple-ascending Dose (MAD): Pooled Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Events (AEs) | 0 | 1 | 1 | 2 | 6 | 10 | 5 | 4 | 6 | 10 | 4 |
| Serious Adverse Events (SAEs) | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Cmax was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
| ng/mL | Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg) | Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg) | Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg) | Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg) | Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg) |
|---|---|---|---|---|---|
| Part A - Pharmacokinetic of KAE609: Maximum Observed Plasma Concentration (Cmax) | 412 ± 101 | 1510 ± 1000 | 2910 ± 1340 | 5930 ± 1190 | 6590 ± 1290 |
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Tmax was calculated from plasma concentration-time data using non-compartmental methods based on the actual time of sample collection and summarized using descriptive statistics.
| Hour (hr) | Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg) | Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg) | Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg) | Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg) | Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg) |
|---|---|---|---|---|---|
| Part A - Pharmacokinetic of KAE609: Time to Reach the Maximum Concentration After Drug Administration (Tmax) | 0.167 (0.0167 to 0.167) | 0.0333 (0.0333 to 0.217) | 0.333 (0.183 to 0.550) | 0.167 (0.167 to 0.183) | 0.167 (0.167 to 0.200) |
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUClast was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
| h*ng/mL | Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg) | Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg) | Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg) | Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg) | Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg) |
|---|---|---|---|---|---|
| Part A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) | 2690 ± 977 | 9540 ± 1640 | 25400 ± 1770 | 53700 ± 20900 | 60800 ± 11600 |
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUCinf was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
| h*ng/mL | Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg) | Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg) | Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg) | Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg) | Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg) |
|---|---|---|---|---|---|
| Part A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) | 2770 ± 990 | 9750 ± 1730 | 25600 ± 1730 | 57400 ± 22100 | 62000 ± 11500 |
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUC0-24hrs was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
| h*ng/mL | Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg) | Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg) | Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg) | Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg) | Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg) |
|---|---|---|---|---|---|
| Part A - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC0-24hrs) | 1450 ± 330 | 4540 ± 673 | 13500 ± 2230 | 23200 ± 7920 | 26200 ± 3600 |
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. T1/2 was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
| Hour (hr) | Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg) | Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg) | Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg) | Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg) | Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg) |
|---|---|---|---|---|---|
| Part A - Pharmacokinetic of KAE609: Terminal Elimination Half-life (T1/2) | 27.7 ± 8.89 | 30.5 ± 6.79 | 21.9 ± 6.76 | 38.9 ± 12.8 | 29.4 ± 5.39 |
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. CL was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
| Milliliter/hour (mL/h) | Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg) | Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg) | Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg) | Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg) | Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg) |
|---|---|---|---|---|---|
| Part A - Pharmacokinetic of KAE609: Clearance From Plasma (CL) Following Drug Administration | 4330 ± 1890 | 3150 ± 507 | 2940 ± 192 | 2430 ± 1120 | 3500 ± 700 |
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Vz was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
| Milliliter (mL) | Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg) | Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg) | Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg) | Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg) | Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg) |
|---|---|---|---|---|---|
| Part A - Pharmacokinetic of KAE609: Apparent Volume of Distribution During Terminal Phase (Vz) | 154000 ± 20400 | 138000 ± 34000 | 92900 ± 29600 | 124000 ± 32700 | 151000 ± 50400 |
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Cmax was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
| ng/mL | Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg) | Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg) |
|---|---|---|
| Day 1 | 3920 ± 999 | 4530 ± 705 |
| Day 5 | 4630 ± 2670 | 5540 ± 2090 |
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Tmax was calculated from plasma concentration-time data using non-compartmental methods based on the actual time of sample collection and summarized using descriptive statistics.
| Hour (hr) | Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg) | Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg) |
|---|---|---|
| Day 1 | 0.100 (0.0333 to 0.500) | 0.167 (0.167 to 0.183) |
| Day 5 | 0.0333 (0.0333 to 0.167) | 0.167 (0.167 to 0.167) |
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUClast was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
| h*ng/mL | Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg) | Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg) |
|---|---|---|
| Part B - Pharmacokinetic of KAE609: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) | 58500 ± 23000 | 121000 ± 56100 |
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. AUC0-24hrs was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
| h*ng/mL | Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg) | Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg) |
|---|---|---|
| Day 1 | 13200 ± 1770 | 16500 ± 2290 |
| Day 5 | 20000 ± 4890 | 40600 ± 11400 |
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. T1/2 was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
| Hour (hr) | Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg) | Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg) |
|---|---|---|
| Day 1 | 25.0 ± 8.16 | 18.1 ± 2.83 |
| Day 5 | 35.5 ± 8.58 | 31.9 ± 12.5 |
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. CL was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
| Milliliter/hour (mL/h) | Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg) | Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg) |
|---|---|---|
| Part B - Pharmacokinetic of KAE609: Clearance From Plasma (CL) Following Drug Administration | 3140 ± 717 | 3160 ± 907 |
Venous whole blood samples were collected for activity-based pharmacokinetics characterization. Vz was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
| Milliliter (mL) | Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg) | Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg) |
|---|---|---|
| Part B - Pharmacokinetic of KAE609: Apparent Volume of Distribution During Terminal Phase (Vz) | 175000 ± 14700 | 173000 ± 29700 |
Collected over On-treatment Adverse events (AEs) and serious AEs (including the All-Cause Mortality data table) are presented from first dose of study treatment until last dose of study treatment plus 30 days post treatment, assessed for up to 4 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg) | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg) | 0/6 (0%) | 1/6 (16.7%) | 2/6 (33.3%) |
| Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part A (Single-ascending Dose (SAD): Pooled KAE609 | 0/30 (0%) | 1/30 (3.3%) | 10/30 (33.3%) |
| Part A (Single-ascending Dose (SAD): Pooled Placebo | 0/9 (0%) | 0/9 (0%) | 5/9 (55.6%) |
| Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part B (Multiple-ascending Dose (MAD): Pooled KAE609 | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| Part B (Multiple-ascending Dose (MAD): Pooled Placebo | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Event | Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg) | Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg) | Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg) | Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg) | Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg) | Part A (Single-ascending Dose (SAD): Pooled KAE609 | Part A (Single-ascending Dose (SAD): Pooled Placebo | Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg) | Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg) | Part B (Multiple-ascending Dose (MAD): Pooled KAE609 | Part B (Multiple-ascending Dose (MAD): Pooled Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Testicular embryonal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 1/30 | 0/9 | 0/6 | 0/6 | 0/12 | 0/6 |
| Testicular malignant teratomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 1/30 | 0/9 | 0/6 | 0/6 | 0/12 | 0/6 |
| Event | Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg) | Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg) | Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg) | Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg) | Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg) | Part A (Single-ascending Dose (SAD): Pooled KAE609 | Part A (Single-ascending Dose (SAD): Pooled Placebo | Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg) | Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg) | Part B (Multiple-ascending Dose (MAD): Pooled KAE609 | Part B (Multiple-ascending Dose (MAD): Pooled Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DizzinessNervous system disorders | 0/6 | 0/6 | 0/6 | 0/6 | 2/6 | 2/30 | 0/9 | 3/6 | 4/6 | 7/12 | 1/6 |
| HeadacheNervous system disorders | 0/6 | 1/6 | 0/6 | 1/6 | 2/6 | 4/30 | 3/9 | 2/6 | 3/6 | 5/12 | 1/6 |
| Semen discolourationReproductive system and breast disorders | 0/6 | 0/6 | 1/6 | 0/6 | 3/6 | 4/30 | 0/9 | 0/6 | 0/6 | 0/12 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/30 | 0/9 | 0/6 | 2/6 | 2/12 | 2/6 |
| FatigueGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/30 | 0/9 | 0/6 | 2/6 | 2/12 | 1/6 |
| Abnormal sensation in eyeEye disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/30 | 0/9 | 0/6 | 0/6 | 0/12 | 0/6 |
| Abdominal discomfortGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/30 | 0/9 | 0/6 | 1/6 | 1/12 | 1/6 |
| DyspepsiaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/30 | 0/9 | 0/6 | 1/6 | 1/12 | 0/6 |
| EructationGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/30 | 0/9 | 1/6 | 0/6 | 1/12 | 0/6 |
| NauseaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/6 | 1/6 | 2/30 | 0/9 | 0/6 | 1/6 | 1/12 | 0/6 |
| Age, Categorical(Participants) | Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg) | Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg) | Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg) | Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg) | Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg) | Part A (Single-ascending Dose (SAD): Pooled Placebo | Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg) | Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg) | Part B (Multiple-ascending Dose (MAD): Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 6 | 6 | 6 | 6 | 9 | 6 | 6 | 6 | 57 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg) | Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg) | Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg) | Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg) | Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg) | Part A (Single-ascending Dose (SAD): Pooled Placebo | Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg) | Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg) | Part B (Multiple-ascending Dose (MAD): Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 2 | 5 | 16 |
| Male | 5 | 4 | 5 | 5 | 5 | 7 | 5 | 4 | 1 | 41 |
| Ethnicity (NIH/OMB)(Participants) | Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg) | Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg) | Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg) | Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg) | Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg) | Part A (Single-ascending Dose (SAD): Pooled Placebo | Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg) | Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg) | Part B (Multiple-ascending Dose (MAD): Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 6 | 6 | 6 | 6 | 9 | 6 | 6 | 6 | 57 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A (Single-ascending Dose (SAD): Cohort A1 (KAE609 10.5 mg) | Part A (Single-ascending Dose (SAD): Cohort A2 (KAE609 30 mg) | Part A (Single-ascending Dose (SAD): Cohort A3 (KAE609 75 mg) | Part A (Single-ascending Dose (SAD): Cohort A4 (KAE609 120 mg) | Part A (Single-ascending Dose (SAD): Cohort A5 (KAE609 210 mg) | Part A (Single-ascending Dose (SAD): Pooled Placebo | Part B (Multiple-ascending Dose (MAD): Cohort B1 (KAE609 60 mg) | Part B (Multiple-ascending Dose (MAD): Cohort B2 (KAE609 120 mg) | Part B (Multiple-ascending Dose (MAD): Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 6 | 6 | 6 | 6 | 6 | 9 | 6 | 6 | 6 | 57 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2020 to primary completion in Nov 2020, 3 months.
Results were first posted in Dec 2021, 1 year 1 month after primary completion.
Of 29 industry-sponsored phase 1 interventional studies under Malaria, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 3 months is below that.
Counting every sponsor, half of 93 studies reached it within 13 months; a quarter within 7 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NITD 609